市場概況

The global Alzheimer’s disease therapeutics market was valued at USD 3.52 億で 2022 and is projected to reach USD 6.66 10億まで 2029, CAGR は 9.2% から 2023 に 2029. Increasing prevalence of Alzheimer’s disease worldwide and investments in therapeutic development are driving market growth. Alzheimer’s disease is a progressive neurodegenerative disorder characterized by memory loss and cognitive impairment. Current treatments provide temporary symptom improvement, but there is a need for effective pharmacological approaches. Laboratory tests and brain-imaging technologies aid in diagnosis. The market primarily consists of symptomatic treatments, with seven approved medications. Clinical trials are in progress, with a focus on Phase II development. The approval of Aducanumab in 2021 and the introduction of novel therapies will contribute to market growth. The market is driven by the rising prevalence of Alzheimer’s disease and significant R&D investments.

レポートは市場規模と成長をカバーしています, セグメンテーション, 競争環境, trends and strategies for global therapeutics of Alzheimer’s disease market. 利害関係者が現在の市場機会を活用できるように、市場の定量的な分析を提供します。. このレポートはまた、市場動向と主要な競合他社のアプローチに基づいて、機会と戦略の上位セグメントを特定します。.

市場セグメンテーション

The market is segmented based on various factors, including drug class, gender, age group, severity, そして地理.
Drug class: ACE inhibitors, NMDA inhibitors, その他
Gender: 男性, 女性
Age group: 65-74 years, 75-84 years, 85 years & その上
Severity type: mild, moderate, severe
地理: 北米, ヨーロッパ, APAC

ACE inhibitors are projected to have a significant share in the global Alzheimer’s disease therapeutics market, but the fastest-growing segment is expected to be other classes of drugs. The recent approval of biologics like Aducanumab (Aduhelm) is anticipated to drive the global Alzheimer’s disease therapeutics market in the future. In terms of gender, women are expected to contribute significantly due to their longer life expectancy and larger population affected by Alzheimer’s disease. Among different age groups, those aged 85 years and above are expected to dominate the market, but the fastest-growing segment will be the population aged 65 years and above. Individuals with mild forms of the disease will hold a significant share in the global therapeutics market, while the fastest-growing segment will be individuals with moderate forms.

In the U.S., the incidence of Alzheimer’s disease was reported to be 229,385 で 2021, and this number is predicted to increase substantially. The United States holds a dominant position in the global market due to factors such as affordability of healthcare, knowledge and awareness, and technological advancements. しかし, China is expected to experience faster growth with a high compound annual growth rate (CAGR) due to the rising geriatric population, increased awareness, and growing healthcare expenditure in the Asia-Pacific (APAC) 領域.

競争環境

The Alzheimer’s Disease (AD) market is primarily dominated by symptomatic treatments, with seven approved medications available. Leading players in the global market include AbbVie Inc, Alzamend Neuro, 株式会社, Alzinova AB, Asceneuron SA, Biogen Inc, Biohaven, 株式会社, BioVie Inc., Denali Therapeutics Inc., Eisai Co., 株式会社, Eli Lilly and Company, GreenValley Inc., ジョンソン & ジョンソン, KeifeRx, LLC, NeuroKine Therapeutics LLC, Novartis AG, UCB SA, Vaccinex Inc, とりわけ. These companies employ strategies such as collaborations, 買収, geographical expansion, research and development investments, and the development of novel drugs to compete in the market.

最近の業界の発展

Biogen announced in April 2022 that the European Medicines Agency (EMA) withdrew the Marketing Authorization Application (MAA) for aducanumab due to insufficient data.

In March 2022, Corium, 株式会社. received FDA approval for Adlarity as a treatment for Alzheimer’s disease patients with mild, moderate, or severe dementia.

In June 2021, Biogen obtained accelerated FDA approval for Aduhelm based on the results of Phase 3 臨床試験 (EMERGE and ENGAGE) conducted on patients with early-stage Alzheimer’s disease and confirmed amyloid pathology.

報告書の範囲

To analyze and forecast the market size of the global therapeutics of Alzheimer’s disease market.
To classify and forecast the global therapeutics of Alzheimer’s disease market based on drug class, gender, age group, severity type, 地理.
To identify drivers and challenges for the global therapeutics of Alzheimer’s disease market.
合併などの競争展開を検討するため & 買収, 協定, コラボレーションとパートナーシップ, 等, in the global therapeutics of Alzheimer’s disease market.
To identify and analyze the profile of leading players operating in the global therapeutics of Alzheimer’s disease market.

このレポートを選択する理由

Gain a reliable outlook of the global therapeutics of Alzheimer’s disease market forecasts from 2023 に 2029 シナリオ全体にわたって.
投資対象となる成長セグメントを特定する.
会社概要と市場データを通じて競合他社に先んじる.
Excel 形式でのシナリオ全体の分析を容易にするための市場予測.
3ヶ月間の戦略コンサルティングとリサーチサポート.
シングルユーザーライセンスに提供される印刷認証.